Dexcom copay assistance card11/17/2023 ![]() ![]() "We are thrilled to partner once again with a leader in diabetes care like Lilly," said Rick Doubleday, chief commercial officer at Dexcom. Lilly and Dexcom will enhance HCP education by jointly sharing information about Lyumjev and the Dexcom G6 and G6 Pro through a variety of channels. "Through this program, we can inspire confidence as clinicians and their patients evaluate new treatment options by showcasing how using these resources together can inform diabetes care." "When it comes to treating diabetes, our partnership with Dexcom has the potential to be meaningful for HCPs who want to help their patients who may be struggling to manage their blood glucose levels after meals," said Adrienne Brown, vice president, U.S. As PPG is often overlooked as a significant contributor to A1C, 1 this partnership also aims to elevate PPG monitoring as an important component of diabetes treatment management. HCPs treating type 1 and type 2 diabetes will be able to assess their patients' glucose levels and time in range with Dexcom G6 or Dexcom G6 Pro, either in blinded or unblinded mode, helping them quickly identify adult patients who struggle to manage their postprandial glucose (PPG) levels (glucose levels following meals) and who may benefit from a treatment like Lyumjev. The program is designed to help clinicians use data to inform diabetes management, including giving visibility to the benefits of a new mealtime insulin. healthcare providers (HCPs) about Lilly's new rapid-acting mealtime insulin Lyumjev ™ (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), now available in U.S. (NASDAQ: DXCM) announced today a joint program for U.S. ![]() 7, 2020 /PRNewswire/ - Eli Lilly and Company (NYSE: LLY) and DexCom, Inc. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |